Table 3 WMHV is associated with longitudinal clinical dementia outcomes in females but not males. A linear mixed effects model was utilized to test for interaction effects between WMHV*visit time, Global18F-flutemetamol SUVR*visit time on CDR-SB
CDR sum of boxes | |||
|---|---|---|---|
|  | β (Std. error) | β 95% Confidence interval | Uncorrected p-value |
Females | |||
Intercept | 4.69 (4.38) | (-3.93, 13.30) | 0.29 |
Age (years) | -0.044 (0.044) | (-0.13, 0.04) | 0.32 |
Visit Time | -0.73 (0.57) | (-1.85, 0.38) | 0.20 |
Global18F-flutemetamol SUVR | 0.34 (2.17) | (-3.94, 4.61) | 0.88 |
WMHV | -0.18 (0.88) | (-0.75, 0.41) | 0.56 |
Scanner Site (Site 2) | 0.15 (0.87) | (-1.55, 1.86) | 0.86 |
Scanner Site (Site 3) | -0.18 (0.88) | (-1.91, 1.55) | 0.84 |
Scanner Site (Site 4) | 0.90 (1.92) | (-2.88, 4.69) | 0.64 |
Scanner Site (Site 5) | 1.74 (2.01) | (-2.23, 5.70) | 0.39 |
Scanner Site (Site 6) | -1.32 (0.73) | (-2.76, 0.12) | 0.073 |
Visit Time * Global18F-flutemetamol SUVR | 3.11 (0.60) | (1.92, 4.30) | 5.50e-07*** |
Visit Time * WMHV | 0.18 (0.072) | (0.04, 0.32) | 0.014* |
Males | |||
Intercept | 0.90 (4.60) | (-8.18, 9.98) | 0.85 |
Age (years) | 0.0084 (0.053) | (-0.10, 0.11) | 0.88 |
Visit Time | -1.48 (-0.71) | (-2.89, -0.07) | 0.039* |
Global18F-flutemetamol SUVR | 2.68 (2.83) | (-2.90, 8.27) | 0.34 |
WMHV | 0.20 (0.42) | (-0.63, 1.02) | 0.64 |
Scanner Site (Site 2) | -0.83 (1.10) | (-3.01, 1.35) | 0.46 |
Scanner Site (Site 3) | -1.00 (1.51) | (-3.99, 1.98) | 0.50 |
Scanner Site (Site 4) | 0.39 (1.50) | (-2.58, 3.35) | 0.80 |
Scanner Site (Site 5) | -0.30 (2.13) | (-4.51, 3.91) | 0.89 |
Scanner Site (Site 6) | -0.31 (1.35) | (-2.99, 2.36) | 0.82 |
Visit Time * Global18F-flutemetamol SUVR | 2.99 (0.72) | (1.56, 4.41) | 7.04e-05*** |
Visit Time * WMHV | 0.019 (0.097) | (-0.17, 0.21) | 0.84 |